• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

    2/14/22 4:46:28 PM ET
    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBT alert in real time by email
    SC 13G/A 1 g020822a.htm SCHEDULE 13G (AMENDMENT NO. 1)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    Global Blood Therapeutics, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.001 Per Share

    (CUSIP Number)

    37890U108

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 37890U108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              183,471 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       183,471 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    183,471 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.3% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 37890U108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              183,471 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       183,471 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    183,471 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.3% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 37890U108
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              37,790 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       37,790 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    37,790 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 37890U108
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,202 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,202 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,202 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 37890U108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              225,463 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       225,463 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    225,463 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.3% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     


    Item 1(a) Name of issuer:
    Global Blood Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    181 Oyster Point Boulevard, South San Francisco, CA 94080
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; (iv) Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to
    Shares held by certain investment funds it manages; and (v) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Hong Kong, and Mr. Cohen have entered into a Joint Filing
    Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1,
    pursuant to which they have agreed to file this Schedule 13G jointly in
    accordance with the provisions of Rule 13d-1(k) of the Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001; and (iii) Point72 Hong Kong is 12th Floor, Chater House,
    8 Connaught Road Central, Hong Kong.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a
    Delaware limited liability company. Point72 Hong Kong is a Hong Kong
    limited liability company. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.001 Per Share
    2(e) CUSIP Number:
    37890U108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 183,471
    (b) Percent of class: 0.3% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 183,471 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 183,471

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 183,471
    (b) Percent of class: 0.3% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 183,471 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 183,471

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 37,790
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 37,790 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 37,790

    4. Point72 Hong Kong Limited
    (a) Amount beneficially owned: 4,202
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 4,202 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 4,202

    5. Steven A. Cohen
    (a) Amount beneficially owned: 225,463
    (b) Percent of class: 0.3% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 225,463 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 225,463

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Hong Kong, and Mr. Cohen own directly no Shares. Pursuant
    to an investment management agreement, Point72 Asset Management maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management
    agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by certain investment funds it manages.
    Pursuant to an investment management agreement, Point72 Hong Kong maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong. As of December 31, 2021, by reason of the provisions of
    Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i)
    Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen may
    be deemed to beneficially own 183,471 Shares (constituting approximately 0.3%
    of the Shares outstanding), (ii) Cubist Systematic Strategies and Mr. Cohen may
    be deemed to beneficially own 37,790 Shares (constituting <0.1% of the Shares
    outstanding) and (iii) Point72 Hong Kong and Mr. Cohen may be deemed to
    beneficially own 4,202 Shares (constituting <0.1% of the Shares outstanding).
    Each of Point72 Asset Management, Point72 Capital Advisors Inc., Cubist
    Systematic Strategies, Point72 Hong Kong, and Mr. Cohen disclaims beneficial
    ownership of any of the securities covered by this statement.
    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the
    securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of the
    securities and were not acquired and are not held in connection with or as a
    participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 14, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $GBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBT

    DatePrice TargetRatingAnalyst
    8/8/2022Outperform → Mkt Perform
    William Blair
    8/8/2022$40.00 → $72.00Hold → Buy
    Canaccord Genuity
    3/28/2022$138.00 → $71.00Outperform
    Wedbush
    2/28/2022$28.00 → $31.00Equal-Weight
    Morgan Stanley
    2/24/2022$92.00 → $86.00Outperform
    Oppenheimer
    12/21/2021$56.00 → $53.00Outperform
    SVB Leerink
    12/14/2021$54.00 → $56.00Outperform
    SVB Leerink
    12/7/2021Market Perform → Outperform
    William Blair
    More analyst ratings

    $GBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Global Blood Therapeutics downgraded by William Blair

      William Blair downgraded Global Blood Therapeutics from Outperform to Mkt Perform

      8/8/22 10:11:32 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Blood Therapeutics upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Global Blood Therapeutics from Hold to Buy and set a new price target of $72.00 from $40.00 previously

      8/8/22 7:23:49 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Global Blood Therapeutics with a new price target

      Wedbush resumed coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $71.00 from $138.00 previously

      3/28/22 8:37:31 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

      Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well

      2/19/25 9:00:00 AM ET
      $AVTE
      $DVAX
      $HZNP
      $MRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

      SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit

      9/15/22 6:00:00 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Financials

    Live finance-specific insights

    See more

    $GBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

      Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace

      8/8/22 6:45:00 AM ET
      $GBT
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

      SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e

      7/29/22 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

      Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo

      6/10/22 3:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

      SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      2/14/23 8:34:46 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

      SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      2/9/23 10:59:20 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Global Blood Therapeutics Inc.

      SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      6/17/22 4:04:33 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Patrick Deval L returned 9,037 shares to the company, closing all direct ownership in the company to cover withholding tax

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:58 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Thompson Alexis A. returned 3,308 shares to the company, closing all direct ownership in the company to satisfy tax liability

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:51 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Morrison Scott W returned 6,637 shares to the company, closing all direct ownership in the company (tax withholding)

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:56 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Leadership Updates

    Live Leadership Updates

    See more
    • GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood

      3/18/21 7:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Announces New Employment Inducement Grants

      SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire

      1/7/21 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development

      SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management

      12/7/20 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Global Blood Therapeutics Inc.

      15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/17/22 8:32:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Global Blood Therapeutics Inc.

      S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/5/22 4:41:14 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Global Blood Therapeutics Inc.

      S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/5/22 4:40:32 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care